Healthy Clinical Trial
Official title:
Development of Applications of the Given® Diagnostic System and Evaluation of Their Performance
The purpose of this study is to support the development of Given® Diagnostic System applications.
This clinical study is designed to support the development of new generations of the Given®
Diagnostic System and Agile™ Patency System that will accomplish better visualization,
better diagnostic capabilities and will improve the system ease of use from the physician as
well as patient's point of view.
*The PillCam™ Capsules Capsule endoscopy using the PillCam™ capsule (Given Imaging Limited,
Yoqneam, Israel) represents the newest imaging modality of the gastrointestinal tract
without the need for invasive techniques, sedation, or radiation exposure1-35. Initially
cleared for marketing in August 2001 as an adjunctive modality, the FDA in 2003 cleared
PillCam™ SB (previously called M2A) as a stand alone tool for detecting small bowel
abnormalities in those patients who meet the device's indications.
The PillCam™ SB provides visualization of the entire small bowel mucosa and is presently
purely a diagnostic test without therapeutic or biopsy potential.
Before capsule endoscopy, enteroscopy was one of the methods for examining the small bowel
tract, but the diagnostic value of this test for a wide variety of specific lesions is low
due to inability to reach the entire length of the small bowel.
Other endoscopic techniques include, Sonde enteroscopy, and intraoperative enteroscopy, but
these are limited for several reasons including significant technical difficulties, length
of procedures, potential risks, and frequently incomplete small bowel examination36-38. To
date more than 400,000 PillCam™ SB capsules were ingested world wide. The Given® Diagnostic
System (GDS) for Small Bowel is now the Gold standard.
Additional PillCam™ capsules were developed and are used for diagnosing the Esophagus as
well as the Colon.
The PillCam™ ESO system received FDA clearance as well as the CE mark early 2005. To date,
thousands of PillCam™ ESO capsules were ingested in both clinical trials and regular
clinical setup worldwide with numerous published clinical studies39-45.
The PillCam™ COLON capsule received CE marking on October 15th, 2006 and is cleared for
marketing in Europe. It is now pending FDA clearance. To date, several hundreds of PillCam™
COLON capsules were ingested in numerous pilot studies and ongoing multi-center studies in
Europe and USA34-35.
*The Agile™ Patency System Small and large bowel strictures are present in a large spectrum
of diseases and clinical situations such as adhesion related diseases, Crohn's disease,
patients who are post abdominal radiation treatment and patients who have undergone
abdominal surgery46. Knowledge of intestinal patency in such patients will aid the physician
in assessment and treatment of the patients.
The current methods for identifying intestinal strictures primarily include small bowel
follow through (SBFT), enteroclysis, computed tomography (CT) and enteroscopy but the
diagnostic value of these tests is low. Advanced strictures are often missed and some of
these methods include radiation and others are invasive.
The Agile™ Patency System is designed to aid the gastroenterologist in verifying the patency
of the GI tract. The system is essentially based on small identification tags, which are
detected by radio frequency (RFID) encapsulated in a disintegrating capsule. The RFID tags
have been marketed for many years for veterinary use. In animals they are injected
sub-dermally and are used for life-long identification, marking and tracking47.
Preliminary results demonstrate that the Agile System performs as intended48. Future
developments of the unique technology which make up the Agile patency capsule will broaden
its range of uses and applications beyond simple patency testing.
Agile ingestions are estimated in the excess of three thousand worldwide.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |